Video
Increased financial coverage for Rezum therapy reaps benefits for patients with BPH
Author(s):
“I think now the government has realized…the work that’s involved in this procedure…[and] we’re now being reimbursed at an appropriate level,” says David M. Albala, MD.
Video Player is loading.
In this video, David M. Albala, MD, discusses how the recent change made by the Centers for Medicare & Medicaid Services regarding Rezum water vapor therapy will open the doors for more patients to receive this minimally invasive treatment. Albala is a urologist at Associate Medical Professionals and chief of urology at Crouse Hospital in Syracuse, New York.
Related Videos
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Alternative treatments and patient communication for genitourinary syndrome of menopause
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
BPH: Strategies for Guiding Patients From Medication to Intervention
Study results affirm effectiveness of evolving prostate cancer therapies
Laura Davis, MD, on link between microplastics and bladder cancer
Related Content
